XL281: Interim Phase I data

In an ongoing, open-label, dose-escalation, U.S. Phase I trial in 29

Read the full 119 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE